The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT2A activity/anti-dopamine D2 activity ratio and drug-induced extrapyramidal symptoms
Aims: Blonanserin is a second‐generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma anti‐5‐HT2A activity/anti‐D2 activity (S/D) ratio and extrapyramidal symptoms (EPS) in blonanserin dosing. Methods: The subjects were 29 ou...
Saved in:
Published in | Psychiatry and clinical neurosciences Vol. 66; no. 2; pp. 146 - 152 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Melbourne, Australia
Blackwell Publishing Asia
01.03.2012
Wiley-Blackwell |
Subjects | |
Online Access | Get full text |
ISSN | 1323-1316 1440-1819 |
DOI | 10.1111/j.1440-1819.2011.02311.x |
Cover
Abstract | Aims: Blonanserin is a second‐generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma anti‐5‐HT2A activity/anti‐D2 activity (S/D) ratio and extrapyramidal symptoms (EPS) in blonanserin dosing.
Methods: The subjects were 29 outpatients with schizophrenia. We assessed EPS using the Drug‐Induced Extrapyramidal Symptoms Scale (DIEPSS). The plasma concentrations were measured by high performance liquid chromatography, and the plasma anti‐D2 and anti‐5‐HT2A activities were measured by [3H]‐spiperone and [3H]‐ketanserin radioreceptor assays.
Results: The results revealed that there were significant correlations between both the plasma concentration and the DIEPSS total score (P < 0.05). A negative correlative tendency was found between the S/D ratio and the DIEPSS total score. Furthermore, the plasma concentrations were divided into a low plasma concentration group and a high plasma concentration group, and the S/D ratios were divided into a low S/D ratio group and a high S/D ratio group. We then compared each group based on the DIEPSS total scores. The score in the high plasma concentration‐low S/D ratio group was significantly higher than in the high plasma concentration‐high S/D ratio, low plasma concentration‐high S/D ratio and low plasma concentration‐low S/D ratio groups (P < 0.05 for all).
Conclusions: These findings indicate that the incidence of EPS during treatment with blonanserin is mainly determined by plasma concentration, but the incidence of EPS may be inhibited when anti‐5HT2A activity is predominant over anti‐D2 activity. |
---|---|
AbstractList | Aims: Blonanserin is a second-generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma anti-5-HT2A activity/anti-D2 activity (S/D) ratio and extrapyramidal symptoms (EPS) in blonanserin dosing. Methods: The subjects were 29 outpatients with schizophrenia. We assessed EPS using the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS). The plasma concentrations were measured by high performance liquid chromatography, and the plasma anti-D2 and anti-5-HT2A activities were measured by [3H]-spiperone and [3H]-ketanserin radioreceptor assays. Results: The results revealed that there were significant correlations between both the plasma concentration and the DIEPSS total score (P<0.05). A negative correlative tendency was found between the S/D ratio and the DIEPSS total score. Furthermore, the plasma concentrations were divided into a low plasma concentration group and a high plasma concentration group, and the S/D ratios were divided into a low S/D ratio group and a high S/D ratio group. We then compared each group based on the DIEPSS total scores. The score in the high plasma concentration-low S/D ratio group was significantly higher than in the high plasma concentration-high S/D ratio, low plasma concentration-high S/D ratio and low plasma concentration-low S/D ratio groups (P<0.05 for all). Conclusions: These findings indicate that the incidence of EPS during treatment with blonanserin is mainly determined by plasma concentration, but the incidence of EPS may be inhibited when anti-5HT2A activity is predominant over anti-D2 activity. Aims: Blonanserin is a second‐generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma anti‐5‐HT2A activity/anti‐D2 activity (S/D) ratio and extrapyramidal symptoms (EPS) in blonanserin dosing. Methods: The subjects were 29 outpatients with schizophrenia. We assessed EPS using the Drug‐Induced Extrapyramidal Symptoms Scale (DIEPSS). The plasma concentrations were measured by high performance liquid chromatography, and the plasma anti‐D2 and anti‐5‐HT2A activities were measured by [3H]‐spiperone and [3H]‐ketanserin radioreceptor assays. Results: The results revealed that there were significant correlations between both the plasma concentration and the DIEPSS total score (P < 0.05). A negative correlative tendency was found between the S/D ratio and the DIEPSS total score. Furthermore, the plasma concentrations were divided into a low plasma concentration group and a high plasma concentration group, and the S/D ratios were divided into a low S/D ratio group and a high S/D ratio group. We then compared each group based on the DIEPSS total scores. The score in the high plasma concentration‐low S/D ratio group was significantly higher than in the high plasma concentration‐high S/D ratio, low plasma concentration‐high S/D ratio and low plasma concentration‐low S/D ratio groups (P < 0.05 for all). Conclusions: These findings indicate that the incidence of EPS during treatment with blonanserin is mainly determined by plasma concentration, but the incidence of EPS may be inhibited when anti‐5HT2A activity is predominant over anti‐D2 activity. |
Author | Suzuki, Hidenobu Gen, Keishi |
Author_xml | – sequence: 1 givenname: Hidenobu surname: Suzuki fullname: Suzuki, Hidenobu email: suzuhide@red.livedoor.com organization: Department of Psychiatry, Tanzawa Hospital, Hadano – sequence: 2 givenname: Keishi surname: Gen fullname: Gen, Keishi organization: Department of Psychiatry, Seimo Hospital, Gunma, Japan |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25550300$$DView record in Pascal Francis |
BookMark | eNo9kctO3DAUhqOKSgXad_AGqYtm8CUeJ4su0LRAK0Rvg1haTnwCniZ2sD1l8mZ9vDoZOl7YR_q-_3jxn2RH1lnIMkTwgqRzvlmQosA5KUm1oJiQBaYs3btX2fEBHKWZUZYTRpZvspMQNhhjxpbkOPu7fgTkoVPROBsezYBqiM8AFsUEhk6FXqHG2QZs9LOEXIvqzlllA3hjPyBlNTIx_JeVjSZPyEVnjUU8v17TC6SaaP6YOJ7PWLtB9cYC-kQPBM3r523abx9yY_W2AY1glz4eRp8CWnUojP0QXR_eZq9b1QV49_KeZneXn9er6_zm29WX1cVNbuiyIDkTTLGyqbAgXHFMgQncMiCsqSmmtW41bQUnglZaVBQzVdKSa0p1UXFRQ8lOs_f7vYN3T1sIUfYmNNB1yoLbBkkwLTHDhJOknr2oKjSqa72yjQly8KZXfpSUc55MnLyPe-_ZdDAeOMFyalRu5FScnIqTU6NyblTu5PfV7TSlfL7PmxBhd8gr_1suBRNc3t9eSYF_8J-XxS_5lf0DqnSqJQ |
ContentType | Journal Article |
Copyright | 2012 The Authors. Psychiatry and Clinical Neurosciences © 2012 Japanese Society of Psychiatry and Neurology 2015 INIST-CNRS |
Copyright_xml | – notice: 2012 The Authors. Psychiatry and Clinical Neurosciences © 2012 Japanese Society of Psychiatry and Neurology – notice: 2015 INIST-CNRS |
DBID | BSCLL IQODW 7TK |
DOI | 10.1111/j.1440-1819.2011.02311.x |
DatabaseName | Istex Pascal-Francis Neurosciences Abstracts |
DatabaseTitle | Neurosciences Abstracts |
DatabaseTitleList | Neurosciences Abstracts |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1440-1819 |
EndPage | 152 |
ExternalDocumentID | 25550300 PCN2311 ark_67375_WNG_70Q5RF4S_J |
Genre | article |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 123 1OB 1OC 24P 29P 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 7.U 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABIVO ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFZJQ AHBTC AHEFC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN EPS ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TKC TR2 TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH ZXP ZZTAW ~02 ~IA ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACUHS ACYXJ ADNMO AFWVQ ALVPJ AAPBV AAUGY AAVGM ABHUG ABPTK ACXME ADAWD ADDAD AFVGU AGJLS IQODW 7TK AAMMB AEFGJ AEYWJ AGQPQ AGXDD AGYGG AIDQK AIDYY |
ID | FETCH-LOGICAL-i2641-373a38c90715a502e370f3e13cb202bdfd2f751729d79203a8285d22d4957be83 |
IEDL.DBID | DR2 |
ISSN | 1323-1316 |
IngestDate | Tue Aug 05 10:20:19 EDT 2025 Sun Oct 22 16:10:05 EDT 2023 Wed Jan 22 17:10:13 EST 2025 Wed Oct 30 09:50:50 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Nervous system diseases Dopamine Serotonin Neuroleptic Psychotropic Toxicity drug-induced extrapyramidal symptoms activity/antidopamine D Catecholamine activity ratio plasma concentration Cerebral disorder Symptomatology Central nervous system disease Neurotransmitter Anti-serotonin 5-HT Blonanserin DIEPSS Extrapyramidal syndrome |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-i2641-373a38c90715a502e370f3e13cb202bdfd2f751729d79203a8285d22d4957be83 |
Notes | ark:/67375/WNG-70Q5RF4S-J ArticleID:PCN2311 istex:845DC69114E9F688EBDDB7D12535D677B5336C01 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PQID | 1028030151 |
PQPubID | 23462 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1028030151 pascalfrancis_primary_25550300 wiley_primary_10_1111_j_1440_1819_2011_02311_x_PCN2311 istex_primary_ark_67375_WNG_70Q5RF4S_J |
PublicationCentury | 2000 |
PublicationDate | March 2012 |
PublicationDateYYYYMMDD | 2012-03-01 |
PublicationDate_xml | – month: 03 year: 2012 text: March 2012 |
PublicationDecade | 2010 |
PublicationPlace | Melbourne, Australia |
PublicationPlace_xml | – name: Melbourne, Australia – name: Richmond |
PublicationTitle | Psychiatry and clinical neurosciences |
PublicationYear | 2012 |
Publisher | Blackwell Publishing Asia Wiley-Blackwell |
Publisher_xml | – name: Blackwell Publishing Asia – name: Wiley-Blackwell |
References | Ochi T, Sakamoto M, Minamida A et al. Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent. Bioorg. Med. Chem. Lett. 2005; 15: 1055-1059. Ishigooka J. An overview of clinical trials of blonanserin, a new antipsychotic drug with dopamine D2 and serotonin 5-HT2A antagonism. Jpn. J. Clin. Psychopharmacol. 2008; 11: 817-833 (in Japanese). Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic durgs on the basis of dopamine D-1, D-2 and serotonin 2 pki values. J. Pharmacol. Exp. Ther. 1989; 251: 238-246. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003; 27: 1159-1172. Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs 2009; 23: 615-625. Murasaki M. Clinical evaluation of blonanserin for schizophrenia-A randomized controlled study comparing blonanserin with haloperidol. Jpn. J. Clin. Psychopharmacol. 2007; 10: 2059-2079 (in Japanese). Murasaki M. Preclinical and clinical features of blonanserin. Jpn. J. Clin. Psychopharmacol. 2008; 11: 855-868 (in Japanese). Yang J, Bahk WM, Cho HS et al. Efficacy and tolerability of blonanserin in the patients with schizophrenia: A randomized, double-blind, risperidone-compared trial. Clin. Neuropharmacol. 2010; 33: 169-175. Suzuki H, Gen K. The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity. Hum. Psychopharmacol. 2010; 25: 342-346. Oka M, Noda Y, Ochi Y et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J. Pharmacol. Exp. Ther. 1993; 264: 158-165. Yanagida H, Morokawa Y. A study of risperidone induced extrapyramidal symptoms- Plasma Risperidone, 9-OH Risperidone concentration and plasma anti 5-HT2A activity/anti-D2 activity. Jpn. J. Clin. Psychopharmacol. 2001; 4: 241-249 (in Japanese). Ohoyama K, Yamamura S, Hamaguchi T et al. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur. J. Pharmacol. 2011; 653: 47-57. Meltzer HY, Nash JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 1991; 43: 587-604. 2009; 23 2010; 33 2011; 653 2010; 25 1991; 43 2001; 4 1989; 251 1996 2003; 27 2008; 11 2005; 15 2007; 10 1993; 264 |
References_xml | – reference: Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003; 27: 1159-1172. – reference: Ishigooka J. An overview of clinical trials of blonanserin, a new antipsychotic drug with dopamine D2 and serotonin 5-HT2A antagonism. Jpn. J. Clin. Psychopharmacol. 2008; 11: 817-833 (in Japanese). – reference: Yang J, Bahk WM, Cho HS et al. Efficacy and tolerability of blonanserin in the patients with schizophrenia: A randomized, double-blind, risperidone-compared trial. Clin. Neuropharmacol. 2010; 33: 169-175. – reference: Ochi T, Sakamoto M, Minamida A et al. Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent. Bioorg. Med. Chem. Lett. 2005; 15: 1055-1059. – reference: Oka M, Noda Y, Ochi Y et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J. Pharmacol. Exp. Ther. 1993; 264: 158-165. – reference: Murasaki M. Preclinical and clinical features of blonanserin. Jpn. J. Clin. Psychopharmacol. 2008; 11: 855-868 (in Japanese). – reference: Meltzer HY, Nash JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 1991; 43: 587-604. – reference: Yanagida H, Morokawa Y. A study of risperidone induced extrapyramidal symptoms- Plasma Risperidone, 9-OH Risperidone concentration and plasma anti 5-HT2A activity/anti-D2 activity. Jpn. J. Clin. Psychopharmacol. 2001; 4: 241-249 (in Japanese). – reference: Murasaki M. Clinical evaluation of blonanserin for schizophrenia-A randomized controlled study comparing blonanserin with haloperidol. Jpn. J. Clin. Psychopharmacol. 2007; 10: 2059-2079 (in Japanese). – reference: Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs 2009; 23: 615-625. – reference: Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic durgs on the basis of dopamine D-1, D-2 and serotonin 2 pki values. J. Pharmacol. Exp. Ther. 1989; 251: 238-246. – reference: Ohoyama K, Yamamura S, Hamaguchi T et al. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur. J. Pharmacol. 2011; 653: 47-57. – reference: Suzuki H, Gen K. The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity. Hum. Psychopharmacol. 2010; 25: 342-346. – volume: 15 start-page: 1055 year: 2005 end-page: 1059 article-title: Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD‐5423, a novel antipsychotic agent publication-title: Bioorg. Med. Chem. Lett. – volume: 25 start-page: 342 year: 2010 end-page: 346 article-title: The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti‐dopamine D and anti‐serotonin 5‐HT activity publication-title: Hum. Psychopharmacol. – volume: 10 start-page: 2059 year: 2007 end-page: 2079 article-title: Clinical evaluation of blonanserin for schizophrenia‐A randomized controlled study comparing blonanserin with haloperidol publication-title: Jpn. J. Clin. Psychopharmacol. – volume: 264 start-page: 158 year: 1993 end-page: 165 article-title: Pharmacological profile of AD‐5423, a novel antipsychotic with both potent dopamine‐D2 and serotonin‐S2 antagonist properties publication-title: J. Pharmacol. Exp. Ther. – volume: 23 start-page: 615 year: 2009 end-page: 625 article-title: The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: A randomized, double‐blind, placebo‐controlled, multicentre study publication-title: CNS Drugs – volume: 251 start-page: 238 year: 1989 end-page: 246 article-title: Classification of typical and atypical antipsychotic durgs on the basis of dopamine D‐1, D‐2 and serotonin 2 pki values publication-title: J. Pharmacol. Exp. Ther. – volume: 33 start-page: 169 year: 2010 end-page: 175 article-title: Efficacy and tolerability of blonanserin in the patients with schizophrenia: A randomized, double‐blind, risperidone‐compared trial publication-title: Clin. Neuropharmacol. – volume: 11 start-page: 855 year: 2008 end-page: 868 article-title: Preclinical and clinical features of blonanserin publication-title: Jpn. J. Clin. Psychopharmacol. – year: 1996 – volume: 4 start-page: 241 year: 2001 end-page: 249 article-title: A study of risperidone induced extrapyramidal symptoms‐ Plasma Risperidone, 9‐OH Risperidone concentration and plasma anti 5‐HT activity/anti‐D activity publication-title: Jpn. J. Clin. Psychopharmacol. – volume: 43 start-page: 587 year: 1991 end-page: 604 article-title: Effects of antipsychotic drugs on serotonin receptors publication-title: Pharmacol. Rev. – volume: 653 start-page: 47 year: 2011 end-page: 57 article-title: Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex publication-title: Eur. J. Pharmacol. – volume: 11 start-page: 817 year: 2008 end-page: 833 article-title: An overview of clinical trials of blonanserin, a new antipsychotic drug with dopamine D and serotonin 5‐HT antagonism publication-title: Jpn. J. Clin. Psychopharmacol. – start-page: 11 year: 1996 end-page: 60 – volume: 27 start-page: 1159 year: 2003 end-page: 1172 article-title: Serotonin receptors: Their key role in drugs to treat schizophrenia publication-title: Prog. Neuropsychopharmacol. Biol. Psychiatry |
SSID | ssj0003361 |
Score | 1.9944851 |
Snippet | Aims: Blonanserin is a second‐generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma... Aims: Blonanserin is a second-generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma... |
SourceID | proquest pascalfrancis wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 146 |
SubjectTerms | Anti-serotonin 5-HT2A activity/anti-dopamine D2 activity ratio Biological and medical sciences blonanserin DIEPSS drug-induced extrapyramidal symptoms Extrapyramidal system High-performance liquid chromatography Medical sciences Mental disorders Nervous system (semeiology, syndromes) Nervous system as a whole Neuroleptics Neurology Neuropharmacology Pharmacology. Drug treatments plasma concentration Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Schizophrenia Serotonin S2 receptors |
Title | The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT2A activity/anti-dopamine D2 activity ratio and drug-induced extrapyramidal symptoms |
URI | https://api.istex.fr/ark:/67375/WNG-70Q5RF4S-J/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1440-1819.2011.02311.x https://www.proquest.com/docview/1028030151 |
Volume | 66 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Bb9MwFLbQDogLsAGiwCYjIU6kxHacNMdpW6kmrYKxid0sO3ZGVJpUSSoNTvyE_aT9Fn4J7yVuWSdOiJuT2E7sfM_5Xvz8mZA3SaS1G2mU2U_TIDIuDlItwiAXLhXAMEKpcTXyyTSenEfHF_LCxz_hWpheH2L9ww0toxuv0cC1ae4YeTcvyVKvxAlUhQ2RTzIRo4z-4ekfJSkhYu97iYDBQ2wG9fy1IqCr2NNXGC6pG-ixvN_qYoOL3ma03Sdp_IjMVo3pI1Fmw2VrhtmPOzqP_6e1j8lDz1zpfg-1bXLPlTvk_omfm39CbgBxtF7F1n0tFtTHgFHgmHQBLH2uaYarJEsv1UurnJpv4AqUaAflO6pLS4u2WWWGl178-nkNF6sW_xpTCUeTM75PcTUGbnrx3mex4PrP4SnoIV9fo91NujptvbyEXEVpAciWwvcIlRRqKGKhRc33-aKt5s1Tcj4-OjuYBH5_iKAAGsdgbBRajDJw75nUMuROJCFgjInM8JAbm1ueJxIYWmqTlIdCo1qf5dyCU5gYNxLPyFZZle45YAEqEXKUMWeTKJY61UA9cxHb0EQsMtGAvO2woBa9BojS9QxD4hKpvkw_qCT8JE_H0Wd1PCB7G2BZFwDXTcKAGg7I6xV6FFgyTs_o0lXLRiHVQwdVsgGJOyysC9_21CJIAwoUokB1KFBX6uPBFFMv_rXgS_IATvM-uO4V2WrrpdsFttWavc6OfgOchCKu |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dbtMwGLXQkIAb_tHKzzAS4oqUJI6T5nLaKGWsFYxO7M5yYgeirUmVptLgikfgkXgWnoTzJWlZJ64Qd4liO7ZzPud89udjxp5HgdZ2oElmP46dILGhE2vhOpmwsQDDcKWm3cjjSTg6Dg5O5El3HBDthWn1IdYTbmQZzXhNBk4T0pesvFmY9OJOihNcxeuDUF4NwDvIE9s_-qMlJUTYeV_C8VCNzbCev5YEwkp9fU4Bk3qBPsvawy422OhFTtv8lIa32NmqOW0syml_WSf99Nslpcf_1N7b7GZHXvlui7Y77Iot7rJr4255_h77CdDxahVe9yWf8y4MjINm8jmI-kzzlDZKFp1aLy8znpzBGyjIFIqXXBeG5_VilRjfPf_1_QceljVNHHOJu9HU3-W0IYPOvXjVJTHw_meoBd_3189485KmTFMtPyNVXhhg2XD8kkhMoUIWgxYtvs7mdTlb3GfHw9fTvZHTHRHh5GByHoZHocUghYfvSS1d34rIBcw8kSa-6ycmM34WSZC02ESx7wpNgn3G9w38wiixA_GAbRVlYbcBBhQi5CD1rImAHx1rsM9MhMZNAi9Igh570YBBzVsZEKWrU4qKi6T6NHmjIveDPBoGH9VBj-1soGWdAd6bxJjq9tizFXwUjJlWaHRhy-VCEdsjH1V6PRY2YFhnvuisBbgGChShQDUoUOfq_d6Erh7-a8an7PpoOj5Uh28n7x6xG0jit7F2j9lWXS3tE5CvOtlpjOo3urAmzQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtQwFLVQkSo2vBEDtBgJsSJD4kcyWVYtw1DoqJRWdGfZsQPRMEmUZKTSFZ_AJ_Et_ZLem2SGTsUKsUvkR-zkXPvc-PqYkJeR0NqNNMrsx7EnjAu9WHPfS7mLOTAMX2rcjXwwDScnYv9UnvbxT7gXptOHWP1wQ8tox2s08NKm14y8XZcM4l6JE6hKMAQ-eVOEQCyQIB39kZLiPOydL-4F0Ir1qJ6_1gR8FV_1GcZL6hpeWdqddbFGRq9S2nZOGt8hs2VvulCU2XDRmGFyfk3o8f909y653VNXutNh7R654fL7ZPOgX5x_QH4D5Gi1DK77lpW0DwKjQDJpCTR9rmmC2yTzXquXFik138EXyNEQ8tdU55ZmTb3MDF89u_j5CxKLBn8bUwl3k2O2Q3E7Bp568abPYsH3n0Mr6B5bpdH2IW2dtlp8hVxZbgHJlsKEhFIKFRSx0KP6x7xsinn9kJyM3x7vTrz-gAgvAx4XwODINR8l4N8HUkufOR75ALKAJ4b5zNjUsjSSQNFiG8XM5xrl-ixjFrzCyLgRf0Q28iJ3jwELUAmXoyRwNhKh1LEG7pny0PpGBMKIAXnVYkGVnQiI0tUMY-Iiqb5M36nI_ySPxuKz2h-Q7TWwrAqA7yZhRPUH5MUSPQpMGddndO6KRa2Q66GHKoMBCVssrApfddUEXAMKFKJAtShQZ-pwd4pXT_614HOyebg3Vh_fTz88JbcgB-sC7Z6RjaZauC1gXo3Zbk3qEiutJXw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+relationship+between+the+plasma+concentration+of+blonanserin%2C+and+its+plasma+anti-serotonin+5-HT2A+activity%2F+anti-dopamine+D2+activity+ratio+and+drug-induced+extrapyramidal+symptoms&rft.jtitle=Psychiatry+and+clinical+neurosciences&rft.au=SUZUKI%2C+Hidenobu&rft.au=GEN%2C+Keishi&rft.date=2012-03-01&rft.pub=Wiley-Blackwell&rft.issn=1323-1316&rft.eissn=1440-1819&rft.volume=66&rft.issue=2&rft.spage=146&rft.epage=152&rft_id=info:doi/10.1111%2Fj.1440-1819.2011.02311.x&rft.externalDBID=n%2Fa&rft.externalDocID=25550300 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1323-1316&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1323-1316&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1323-1316&client=summon |